SCHEMBL22407724

SCHEMBL22407724

CCC(C(=O)Nc1c(C)cccc1C)N1CCCCCC1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.66
▸ POLB P06746 1/20 0.55
▸ CYP3A4 P08684 3/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ SLC6A2 P23975 3/20 0.48
▸ SLC6A4 P31645 3/20 0.48
▸ SLC6A3 Q01959 3/20 0.48
▸ KCNK3 O14649 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ KCNH2 Q12809 2/20 0.44
▸ EPHX1 P07099 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18485516 1.00 ATM (0.66) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL18485512 0.99 ATM (0.68) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL22203980 0.89 ATM (0.63) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL22405856 0.88 ATM (0.52) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL31678662 0.88 ATM (0.52) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL22407702 0.86 POLB (0.55) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL22407648 0.84 ATM (0.46) ATMPOLBCYP3A4CYP2D6CYP2C19
Bromide SCHEMBL22412696 0.83 ATM (0.59) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL22746436 0.81 ATM (0.97) ATMPOLBCYP3A4CYP2D6CYP2C19
SCHEMBL18486453 0.81 ATM (0.97) ATMPOLBCYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3938345-B1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE NOCION THERAPEUTICS INC (US) 2026-05-06 — — EP disclosed
US-20250263375-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2025-08-21 — — US disclosed
US-20230192613-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2023-06-22 — — US disclosed
US-11603355-B2 Charged ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-03-14 — — US disclosed
EP-3938345-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. (US) 2022-01-19 — — EP disclosed
US-10968179-B2 Charged ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2021-04-06 — — US disclosed
US-20210061763-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE NOCION THERAPEUTICS INC (US) 2021-03-04 — — US disclosed
US-10780083-B1 Charged ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2020-09-22 — — US disclosed
US-20200290953-A1 Charged Ion Channel Blockers and Methods for Use Nocion Therapeutics, Inc. 2020-09-17 — — US disclosed
US-20200289490-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. 2020-09-17 — — US disclosed
WO-2020185830-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. (US) 2020-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200290953-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV2, TRPV5 ATM 4775/4885POLB 1996/4885CYP3A4 3620/4885
US-20200289490-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE TRPV1, TRPV2, TRPV5 ATM 4774/4885POLB 1989/4885CYP3A4 3576/4885
US-20250263375-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV2, TRPV5 ATM 4775/4885POLB 1996/4885CYP3A4 3620/4885
US-10780083-B1 Charged ion channel blockers and methods for use TRPV1, TRPV2, TRPV5 ATM 4774/4885POLB 1989/4885CYP3A4 3576/4885
US-11603355-B2 Charged ion channel blockers and methods for use TRPV1, TRPV2, TRPV5 ATM 4775/4885POLB 1996/4885CYP3A4 3620/4885
US-20230192613-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV2, TRPV5 ATM 4775/4885POLB 1996/4885CYP3A4 3620/4885
US-10968179-B2 Charged ion channel blockers and methods for use TRPV1, TRPV2, TRPV5 ATM 4775/4885POLB 1996/4885CYP3A4 3620/4885
US-20210061763-A1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE TRPV1, TRPV2, TRPV5 ATM 4775/4885POLB 1996/4885CYP3A4 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback